Artivion, Inc. (AORT)

Artivion's stock price increased significantly over the past six months. In August 2025, the company reported Q2 2025 earnings, beating analyst estimates, which led to a stock price increase. Analysts have maintained positive recommendations for Artivion. There was an insider sale of shares in June 2025. In November 2024, Artivion disclosed a cybersecurity incident that caused disruptions, but these were largely mitigated.

Demand for Artivion's vascular preservation services traditionally exhibits seasonality, with the lowest demand occurring in the fourth quarter due to fewer vascular surgeries being scheduled during the winter holiday months.

Artivion, Inc. (AORT) is a global medical technology company focused on implantable tissue products and surgical devices for cardiac and vascular surgery. Its product portfolio includes aortic stent grafts, surgical sealants, On-X® mechanical heart valves, and implantable cardiac and vascular human tissues. Key products are BioGlue surgical adhesive, PhotoFix bovine pericardial patch, and aortic arch stent grafts like E-vita Open NEO.

Artivion has manufacturing and processing facilities in the United States and Europe. Its commercial teams serve hospitals and surgical centers across North America, Latin America, Europe, the Middle East, and Asia-Pacific, supported by direct sales and distribution partnerships in over 100 countries.

Artivion aims to be a leader in technologies for patients with aortic disease. However, an adverse event report was filed with the FDA regarding an Aortic On-X Heart Valve, describing it as "quite noisy" and causing "loss of cognition function", potentially impacting the brand's reputation.

Institutions hold a significant portion of Artivion's stock. Top institutional shareholders include Peregrine Capital Management LLC, Calamos Advisors LLC, State of Alaska Department of Revenue, and Louisiana State Employees Retirement System. Insiders also hold a portion of the company's stock.